Trinity Biotech plc Reports Strong Q2 2024 Results, Driven by TrinScreen HIV Business

Strategic Insights -

Trinity Biotech plc, a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, announced its Q2 2024 financial results today. The company reported strong revenue and profitability improvements, driven by the TrinScreen HIV business. The company's existing business segments, including TrinScreen HIV and Point-of-Care products, showcased impressive growth, with TrinScreen HIV driving a 14.0% year-on-year revenue increase and 7.7% quarter-on-quarter revenue increase. The company's Point-of-Care products also experienced significant growth, with 119% year-on-year revenue growth and 53% quarter-on-quarter revenue growth. These results were achieved through the company's disciplined execution on profitability-enhancing initiatives, which contributed to a 59% improvement in the operating loss (before restructuring and impairment charges) compared to Q2 2023 and a 45% improvement compared to Q1 2024.

Key Takeaways:

  • The TrinScreen HIV business drove a 14.0% year-on-year revenue increase and 7.7% quarter-on-quarter revenue increase, contributing to the overall 14% year-on-year revenue increase for the company.
  • The Point-of-Care product revenue grew 119% year-on-year and 53% quarter-on-quarter, with significant growth expected to continue into 2025.
  • The company reiterates guidance of approximately $20 million of annualized run-rate EBITDASO on annualized run-rate revenues of approximately $75 million by Q2 2025.
  • The Comprehensive Transformation Plan, initiated by the new management team, is on track to deliver further gross margin and EBITDASO improvements through 2024 and into 2025.
  • Key developments in the plan include efforts to consolidate and offshore manufacturing, optimize the supply chain, and centralise and offshore corporate services.

Statistics:

  • TrinScreen HIV business revenue increased by 14.0% year-on-year and 7.7% quarter-on-quarter.
  • Point-of-Care product revenue grew 119% year-on-year and 53% quarter-on-quarter.
  • The operating loss (before restructuring and impairment charges) decreased by 59% compared to Q2 2023 and by 45% compared to Q1 2024.
  • The company aims to achieve approximately $20 million of annualized run-rate EBITDASO on annualized run-rate revenues of approximately $75 million by Q2 2025.
  • The company expects to cease manufacturing at its Kansas City site by the end of 2024.

Sources:

  • Trinity Biotech plc. (2024, August 14). Trinity Biotech Announces Q2 2024 Financial Results. Retrieved from https://www.trinitybiotech.com/wp-content/uploads/2024/08/Trinity-Biotech-Announces-Q2-2024-Financial-Results.pdf
  • Trinity Biotech plc. (2024). Comprehensive Transformation Plan. Retrieved from https://www.trinitybiotech.com/comprehensive-transformation-plan